![HUTCHMED (China) Limited logo](/logos/0013.HK.webp)
HUTCHMED (China) Limited
HKEX:0013.HK
Overview | Financials
Company Name | HUTCHMED (China) Limited |
Symbol | 0013.HK |
Currency | HKD |
Price | 29.05 |
Market Cap | 25,313,000,447 |
Dividend Yield | 0% |
52-week-range | 19 - 35.9 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Wei-Guo Su B.Sc., Ph.D. |
Website | https://www.hutch-med.com |
An error occurred while fetching data.
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD